BRIEF-DSMB positively assesses Mabion's comparative study of MabionCD20 drug

* Said on Thursday that Data and Safety Monitoring Board

(DSMB) assessed clinical data and safety data obtained from

patients in comparative study of the drug MabionCD20 and the

MabThera reference product (MabThera)

Read more